Form 4: Guardant Health Executive Craig Eagle Reports Stock Option and Restricted Stock Unit Awards
SEC Filing
Craig Eagle, Chief Medical Officer of Guardant Health, reports the acquisition of stock options and restricted stock units.
Summary
- Craig Eagle, Chief Medical Officer of Guardant Health, filed a Form 4 with the SEC.
- The filing reports the grant of a stock option for 24,363 shares at an exercise price of $43.10 on March 12, 2025.
- These options vest over three years, with 33% vesting on April 1, 2026, and the remaining 67% vesting in equal monthly installments over the subsequent two years.
- The filing also reports the grant of 16,242 restricted stock units (RSUs) on March 12, 2025.
- These RSUs also vest over three years, with 33% vesting on April 1, 2026, and the remaining 67% vesting in equal quarterly installments over the subsequent two years.
- Following these transactions, Eagle directly owns 24,363 stock options and 16,242 RSUs.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, indicating confidence in the company's future.
Positives
- The grant of stock options and RSUs to the Chief Medical Officer aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This type of equity compensation is common in the biotech industry to attract and retain key executives.
Comparison to Industry Standards
- Equity grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Illumina, Roche, and Exact Sciences also utilize stock options and RSUs to incentivize their leadership teams.
- The vesting schedules described are typical for such grants, aligning executive interests with long-term shareholder value.
Stakeholder Impact
- The equity grants incentivize the Chief Medical Officer to contribute to the long-term success of the company, benefiting shareholders.
- Employees may view the grants as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of stock option and restricted stock unit awards |
| 03/12/2025 | Date of earliest transaction |
| 03/13/2025 | Date of signature on the Form 4 filing |
| 04/01/2026 | First vesting date for 33% of the stock options and RSUs |
| 03/12/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.